Literature DB >> 12682072

Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein.

Seetharaman Balasenthil1, Ratna K Vadlamudi.   

Abstract

PELP1 (proline-, glutamic acid-, and leucine-rich protein-1 (also referred to as MNAR, or modulator of nongenomic activity of estrogen receptor)), a recently identified novel coactivator of estrogen receptors, is widely expressed in a variety of 17 beta-estradiol (E2)-responsive reproductive tissues and is developmentally regulated in mammary glands. pRb (retinoblastoma protein), a cell cycle switch protein, plays a fundamental role in the proliferation, development, and differentiation of eukaryotic cells. To study the putative function of PELP1, we established stable MCF-7 breast cancer cell lines overexpressing PELP1. PELP1 overexpression hypersensitized breast cancer cells to E2 signaling, enhanced progression of breast cancer cells to S phase, and led to persistent hyperphosphorylation of pRb in an E2-dependent manner. Using phosphorylation site-specific pRb antibodies, we identified Ser-807/Ser-811 of pRb as a potential target site of PELP1. Interestingly, PELP1 was discovered to be physiologically associated with pRb and interacted via its C-terminal pocket domain, and PELP1/pRb interaction could be modulated by antiestrogen agents. Using mutant pRb cells, we demonstrated an essential role for PELP1/pRb interactions in the maximal coactivation functions of PELP1 using cyclin D1 as one of the targets. Taken together, these findings suggest that PELP1, a steroid coactivator, plays a permissive role in E2-mediated cell cycle progression, presumably via its regulatory interaction with the pRb pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12682072      PMCID: PMC1262660          DOI: 10.1074/jbc.M212822200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Discovery of a regulatory motif that controls the exposure of specific upstream cyclin-dependent kinase sites that determine both conformation and growth suppressing activity of pRb.

Authors:  B Driscoll; A T'Ang; Y H Hu; C L Yan; Y Fu; Y Luo; K J Wu; S Wen; X H Shi; L Barsky; K Weinberg; A L Murphree; Y K Fung
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

2.  Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4.

Authors:  E Neuman; M H Ladha; N Lin; T M Upton; S J Miller; J DiRenzo; R G Pestell; P W Hinds; S F Dowdy; M Brown; M E Ewen
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

Review 3.  Estrogen regulation of cell cycle progression in breast cancer cells.

Authors:  O W Prall; E M Rogan; R L Sutherland
Journal:  J Steroid Biochem Mol Biol       Date:  1998-04       Impact factor: 4.292

Review 4.  The regulation of E2F by pRB-family proteins.

Authors:  N Dyson
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

5.  c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.

Authors:  O W Prall; E M Rogan; E A Musgrove; C K Watts; R L Sutherland
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

6.  Generation and analysis of 280,000 human expressed sequence tags.

Authors:  L D Hillier; G Lennon; M Becker; M F Bonaldo; B Chiapelli; S Chissoe; N Dietrich; T DuBuque; A Favello; W Gish; M Hawkins; M Hultman; T Kucaba; M Lacy; M Le; N Le; E Mardis; B Moore; M Morris; J Parsons; C Prange; L Rifkin; T Rohlfing; K Schellenberg; M Bento Soares; F Tan; J Thierry-Meg; E Trevaskis; K Underwood; P Wohldman; R Waterston; R Wilson; M Marra
Journal:  Genome Res       Date:  1996-09       Impact factor: 9.043

7.  A comparison of expressed sequence tags (ESTs) to human genomic sequences.

Authors:  T G Wolfsberg; D Landsman
Journal:  Nucleic Acids Res       Date:  1997-04-15       Impact factor: 16.971

Review 8.  The estrogen receptor family.

Authors:  M Warner; S Nilsson; J A Gustafsson
Journal:  Curr Opin Obstet Gynecol       Date:  1999-06       Impact factor: 1.927

9.  Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.

Authors:  O W Prall; B Sarcevic; E A Musgrove; C K Watts; R L Sutherland
Journal:  J Biol Chem       Date:  1997-04-18       Impact factor: 5.157

10.  pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells.

Authors:  R J Lee; C Albanese; R J Stenger; G Watanabe; G Inghirami; G K Haines; M Webster; W J Muller; J S Brugge; R J Davis; R G Pestell
Journal:  J Biol Chem       Date:  1999-03-12       Impact factor: 5.157

View more
  33 in total

1.  Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.

Authors:  Vijay K Gonugunta; Gangadhara R Sareddy; Samaya Rajeshwari Krishnan; Valerie Cortez; Sudipa Saha Roy; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Mol Cancer Ther       Date:  2014-03-31       Impact factor: 6.261

2.  Significance of ER-Src axis in hormonal therapy resistance.

Authors:  Sreeram Vallabhaneni; Binoj C Nair; Valerie Cortez; Rambabu Challa; Dimple Chakravarty; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Breast Cancer Res Treat       Date:  2010-12-24       Impact factor: 4.872

3.  Epigenetic Reactivation of Estrogen Receptor: Promising Tools for Restoring Response to Endocrine Therapy.

Authors:  Neeraj K Saxena; Dipali Sharma
Journal:  Mol Cell Pharmacol       Date:  2010

Review 4.  Estrogen and progesterone receptors: from molecular structures to clinical targets.

Authors:  Stephan Ellmann; Heinrich Sticht; Falk Thiel; Matthias W Beckmann; Reiner Strick; Pamela L Strissel
Journal:  Cell Mol Life Sci       Date:  2009-03-31       Impact factor: 9.261

5.  Regulation of aromatase induction by nuclear receptor coregulator PELP1.

Authors:  Ratna K Vadlamudi; Rajib Rajhans; Dimple Chakravarty; Binoj C Nair; Sujit S Nair; Dean B Evans; Shiuan Chen; Rajeshwar Rao Tekmal
Journal:  J Steroid Biochem Mol Biol       Date:  2009-09-30       Impact factor: 4.292

6.  Increased PELP1 expression in rat periodontal ligament tissue in response to estrogens treatment.

Authors:  Jing Wang; Qiang Zhu; Shujun Song; Jun Dong; Lixin Shi; Ran Tao; Yin Ding; Baofa Hong
Journal:  J Mol Histol       Date:  2013-02-24       Impact factor: 2.611

Review 7.  Minireview: Deciphering the Cellular Functions of PELP1.

Authors:  Preethi Ravindranathan; Carol A Lange; Ganesh V Raj
Journal:  Mol Endocrinol       Date:  2015-07-09

8.  Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors.

Authors:  Ratna K Vadlamudi; Seetharaman Balasenthil; Russell R Broaddus; Jan-Ake Gustafsson; Rakesh Kumar
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

Review 9.  PELP1: A novel therapeutic target for hormonal cancers.

Authors:  Dimple Chakravarty; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  IUBMB Life       Date:  2010-03       Impact factor: 3.885

10.  The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signaling.

Authors:  Vladimir M Popov; Jie Zhou; L Andrew Shirley; Judy Quong; Wen-Shuz Yeow; Jennifer A Wright; Kongming Wu; Hallgeir Rui; Ratna K Vadlamudi; Jie Jiang; Rakesh Kumar; Chenguang Wang; Richard G Pestell
Journal:  Cancer Res       Date:  2009-07-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.